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Background: Tight correlation between host circulating CD8+ T cell-mediated immune response and control of
viral replication is classical characteristic of long-term HCV infection. CD8+ T cell maturation/activation markers are
expected to be associated with viral replication and disease progression in chronic HCV infection. The aim of the
present study was to explore novel markers on CD8+ T cells with ability to evaluate HCV viral replication and
disease progression.
Methods: PBMCs were isolated from 37 chronic HCV-infected patients and 17 healthy controls. Distributed pattern
of CD8+ T cells subsets and expression of PD-1, CD38, HLA-DR and CD127 were analyzed by flow cytometry. The
correlation between expression of surface markers and HCV viral load or ALT was studied.
Results: Declined naïve and increased TEMRA CD8+ T subsets were found in HCV-infected individuals compared
with healthy controls. Percentage and MFI of PD-1, CD38 and HLA-DR on all CD8+ T cell subsets were higher in
HCV-infected patients than healthy controls. In contrast, CD127 expression on CD8+ TCM showed an opposite
trend as PD-1, CD38 and HLA-DR did. In chronic HCV infection, MFI of PD-1 on CD8+ TEM (p < 0.0001) and TEMRA
(p = 0.0015) was positively correlated with HCV viral load while HLA-DR expression on non-naive CD8+ T cell
subsets (p < 0.05) was negatively correlated with HCV viral load.
Conclusion: PD-1 level on peripheral CD8+ TEM/TEMRA was highly correlated with HCV viral load in chronic
HCV-infected patients, which made PD-1 a novel indicator to evaluate HCV replication and disease progression in
chronic hepatitis C patients.
Background
Hepatitis C virus (HCV) infection was prevalent in several
provinces of China due to unsanitary blood collection his-
tory in 1990’s [1-3]. Traditionally, viral load and alanine
aminotransferase/aspartate aminotransfearse (ALT/AST)
were used as clinical surrogates to evaluate hepatitis C dis-
ease progression and effect of antiviral therapies. Since
dysfunctions of viral specific CD8+ T cell immune
responses are closely associated with HCV replication
[4-6], simple and easy-manipulated CD8+ T cell matura-
tion/activation markers which are able to assess viral repli-
cation and/or disease progression are desired.
According to the expression of CD45RA and another
co-stimulating molecule CD62L, CCR7 or CD27, CD8+
T cells can be divided into four different subsets: Naïve,
TCM (central memory T cell), TEM (effector memory T
cell) and TEMRA (CD45RA+ effector memory T cell)
[7-12]. Following priming by infected HCV or HIV-1,
naïve cells can clonally expand and subsequently differ-
entiate into TEMRA/TEM cells. Once virus was cleared,
most activated CD8+ T cells experienced apoptosis and
finally a minority of survived effector cells becomes
TCM cells[13,14]. It has been proposed that unbalanced
distribution of circulating CD8+ T cell subsets and
impairment of homing capacity and effector function
are closely associated with HCV/HIV-1-specific immune
tolerance and viral persistence [15-19].
The PD-1(programmed death-1) molecule is expressed
on lymphocytes, especially on T and B cells, and is an
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Interaction between PD-1 and its ligand PD-L1 (pro-
grammed death ligand 1), which mainly expressed on
antigen-presenting cells (APC) such as dendritic cells
(DCs) and macrophages, has been postulated to nega-
tively regulate T cell activation and immune evasion in
viral infection and autoimmune diseases[21-23]. Higher
level of PD-1 expression in HCV infection was docu-
mented [24-26]. Urbani et al.[24] demonstrated that
PD-1 expression in acute HCV infection seemed to be a
signature of functional HCV-specific CD8 T cell exhaus-
tion. Golden-Mason et al. [25] and Radziewicz et al.[26]
showed that PD-1/PD-L1 pathway was critical in persis-
tent of HCV infection and represented a potential novel
target for reversible immune dysfunction. Whereas, so
far, no defined data were clearly and systematically
depicted PD-1 expression on CD8+ T cell subsets in
chronically HCV infected patients.
As a subunit (a chain) of IL-7 receptor, CD127/IL-7 sys-
tem plays an essential role in maintaining homeostasis of
circulating T cells, including naïve and memory T cells
under physiological as well as immune disordered condi-
tions[27,28]. Though the exact role of CD127 in pathogen-
esis of HCV and HIV-1 infection is still undetermined,
numerous studies showed that CD127 might be a potential
predicator of clinical status in both adults and children
infected by HCV and/or HIV-1[29-31]. CD38 and HLA-
DR molecules were regarded as classic immune activators
and were widely used to gating activated T cells in cellular
immunology [32-34]. Since HCV infection could induce
CD8+ T cell activation and impaired balance of T cell-
homeostasis, it will provide more detailed information to
assess the status of CD8+ T cell maturation (CD45RA and
CD27), activation (CD38 and HLA-DR), inactivation (PD-
1) and generation of immune memory (CD127) in chronic
HCV-infected patients.
Thus, the aim of the present study was to analyze the
status of CD8+ T cell maturation/activation in chronic
HCV infected patients in comparison with healthy con-
trols and to explore novel markers on CD8+ T cells




54 subjects were recruited and divided into two groups:
chronic HCV-infected patients (n = 37), and healthy
controls (n = 17). All participants were residents of a
village of Henan province and interviewed by trained
and qualified staffs using standardized questionnaire. All
HCV-infected patients were former blood donors
(FBDs) and negative for HBV and HIV infection, which
w e r ed e f i n e db ys e r o n e g a t i v i t yw i t he n z y m ei m m u n o a s -
says and Western Blot respectively. HCV infection was
confirmed by detectable plasma HCV viral load mea-
sured by Abbott RealTime™ HCV Amplification Kit (Des
Plaines, IL, USA) and by reactive serum HCV antibodies
measured by Abbott ARCHITECT anti-HCV system
(Des Plaines, IL, USA). Healthy donors were negative
for HCV, HBV and HIV-1 infection. Importantly, none
of HCV-infected patients had received any HCV-specific
antiviral therapy. The study was approved by institu-
tional review authorities and informed consent forms
were signed by all participants.
Clinical Biochemical Tests
Liver associated enzymes including ALT, AST, g-GT
(g - glutamyltransferase), ALP (alkaline phosphatase) and
other variables such as albumin, globulin and albumin/
globulin ratio in serum were measured by clinical standar-
dized methods.
Flow Cytometry Analysis
Peripheral blood mononuclear cells were isolated from
heparinized blood and expression of surface markers on
CD8+ T cells were analyzed by BD FACSAria (San Jose,
CA) compensated with single fluorochromes and driven
by BD FACSDiva software (San J o s e ,C A ) .D a t aa n a l y s i s
was performed using FlowJo (San Carlos, CA).
Fluorochrome-labeled monoclonal antibodies specific for
CD4-APC-Cy7, CD4-PE-Texas Red, CD8-PE-Cy7,
CD45RA-PE-Cy5, CD45RA-APC, CD27-PE, CD27-APC
Cy7, CCR7-PE Cy7, CD25-APC, PD-1-FITC, HLA-DR-
APC, CD38-FITC were supplied by BD Pharmingen (San
Diego, CA), and CD127-Pacific blue and CD8-Pacific Blue
were supplied by eBioscience (San Diego, CA). CD3-ECD
was purchased from Beckman Coulter (Fullerton, CA).
Statistical analysis
Data were analyzed with GraphPad Prism 5 software
(San Diego, CA, USA). Variables were compared using
nonparametric tests (Mann-Whitney U test) and corre-
lation was performed using Spearman rank correlation
coefficient test. P values < 0.05 was considered as statis-
tical difference.
Results
Characteristics of study populations
Two groups of participants were recruited in this study:
chronic HCV-infected patients and healthy controls.
The demographic and laboratory characteristics of all
participants were summarized in Table 1.
Impact of HCV infection on distribution of CD8+
T cell subsets
CD8+ T cells can be divided into four subsets according to
CD45RA and CD27 expression: naïve (CD45RA+CD27+),
TCM (CD45RA-CD27+), TEM (CD45RA-CD27-) and
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T cell subsets was shown in Figure 1A (a-f). The percen-
tage of naïve CD8+ T cells in HCV infection was signifi-
cantly decreased compared with healthy controls (p =
0.0003, Figure 1B), while percentage of TEMRA showed
an opposite trend, which was increased in HCV infection
(p < 0.0001, Figure 1B). Also, as shown in Figure 1C, the
majority (more than 90%) of CD45RA+CD27+ CD8+
T cells were corresponding to CD45RA+CCR7+ CD8+
T cells both in HCV chronic-infected patients and healthy
controls.
Expression of maturation/activation markers on total
CD8+ T cells in HCV infection
PD-1, CD38, HLA-DR and CD127 expression on total
CD8+ T cells were measured (Figure 2A) and results
were shown as mean fluorescence intensity (MFI) and
percentage of positive cells (Figure 2B). Significantly
higher PD-1 (p < 0.0001), CD38 (p < 0.0001) and HLA-
DR (p < 0.0001) expression were observed in HCV-
infected patients (Figure 2A and 2B). Different from
PD-1, CD38, and HLA-DR expression, MFI of CD127
was declined in HCV infection (p = 0.0147 < 0.05) com-
pared to healthy controls (Figure 2B). However, no sig-
nificant difference was found when calculation was
performed using percentage of CD127 positive cells
(Figure 2B).
Different patterns of PD-1, CD38, HLA-DR and CD127
expression on CD8+ T cell subsets in HCV infection
The expression patterns of markers (PD-1, CD38, HLA-DR
and CD127) on different CD8+ T cell subsets were mea-
sured in HCV-infected patients. As shown in Figure 3A, all
subsets of CD8+ T cells in HCV-infected patients
expressed higher PD-1 in both MFI and percentage (p <
0.0001), compared with healthy controls. The highest MFI
of PD-1 or proportion of PD-1 positive cells were found in
TCM subset, and to a less degree were naïve cells in HCV-
infected patients. Similar to PD-1, HCV-infected patients
expressed significantly higher MFI and percentage with
regards to expression of CD38 and HLA-DR on most CD8
+ T cell subsets (Figure 3B). MFI of CD38 on all CD8+
T cell subsets increased in HCV infection than healthy
controls (p < 0.0001). Both MFI and percentage of HLA-
DR positive cells were increased on all CD8+ T cell subsets
in the HCV-infected patients than healthy controls (Figure
3 C ,p<0 . 0 0 0 1 ) .W ea l s of o u n dt h a tH L A - D Re x p r e s s e d
higher on memory CD8+ T cells (TCM/TEM) than effec-
tor subsets (TEMRA), indicating HLA-DR expression
would drop when CD8+ T cells developed from memory
to effector status, though both memory and effector CD8+
T cell subsets expressed significantly higher HLA-DR than
naïve CD8+ T cells. As shown in Figure 3D, MFI of
CD127 was declined on TCM and TEM in HCV-infected
subjects (p < 0.05) compared with healthy controls, while
no similar trend was found when CD127 expression was
presented as percentage of positive cells.
Correlation analysis of maturation/activation markers on
CD8+ T cell subsets with traditional clinical indicators
Correlation between HCV viral load or ALT and T cell
markers was summarized in Figure 4. PD-1 expression
on TEM and TEMRA was positively correlated with
HCV viral load in HCV infection (TEM: r = 0.6189, p <
0.0001; TEMRA: r = 0.5022, p = 0.0015; Figure 4A). No
correlation was found between total CD8+ T cells or
naïve/TCM subsets and HCV viral load. In contrast,
HLA-DR expression on total CD8+ T cells (r = -0.3431,
Table 1 Demographic and laboratory characteristics of participants enrolled in the study
Characteristics Healthy control HCV-infected patients
(n = 17, F/M = 10/7) (n = 37, F/M = 21/16)
Age (years) (mean ± SD) 42.034 ± 14.321 47.105 ± 16.990
ALT
b level(IU/mL) (mean ± SD) n.a.
a 43.324 ± 26.601
AST
c level(IU/mL) (mean ± SD) n.a. 39.250 ± 18.181
Y-G T
d (IU/mL) (mean ± SD) n.a. 28.916 ± 25.282
ALP
e level(IU/mL) (mean ± SD) n.a. 78.321 ± 36.270
Albumin level(g/L) (mean ± SD) n.a. 47.354 ± 6.966
Total protein level(g/L) (mean ± SD) n.a. 75.461 ± 15.782
Ratio of albumin to globulin (mean ± SD) n.a. 1.410 ± 0.864
Total bilirubin level(μmol/L) (mean ± SD) n.a. 12.280 ± 3.761
Direct bilirubin level (μmol/L) (mean ± SD) n.a. 5.214 ± 5.390
Hemoglobin(g/L) (mean ± SD) n.a. 139.620 ± 14.551
HCV genotyping (1b/2a) n.a. 16/21
HCV RNA(log10IU/ml) (mean ± SD) n.a. 5.747 ± 1.244
a n.a., not available or not applicable;
bALT, Alanine aminotransferase;
c AST, Aspartate aminotransfearse;
d góGT, gó glutamyltransferase;
eALP, Alkaline
phosphatase.
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-0.3618, p = 0.0278) and TEMRA (r = -0.3489, p =
0.0343) was negatively correlated with HCV viral load in
HCV-infected patients (Figure 4A). No correlation
between CD38 and CD127 (Figure 4A) expression and
HCV viral load appeared in HCV-infected subjects.
Unfortunately, we didn’t find any correlation between
MFI of PD-1, CD38, HLA-DR or CD127 and ALT levels
in HCV infected patients (Figure 4B).
Percentage of CD38+HLA-DR+ cells in HCV chronic
infection and its correlation with traditional clinical
indicators
Since several groups[33,35] reported that virus (including
HIV and HCV)-specifically activated T cells presenting
CD38+ HLA-DR+ (double-positive) phenotype, we also
analyzed proportion of CD38+ HLA-DR+ both in total
CD8+ T cells and four different subsets. The results
showed that percentage of CD38+ HLA-DR+ double posi-
tive cells was increased in all four CD8+ T cell subsets as
well as total CD8+ T cells compared to healthy controls (p
< 0.0001, Figure 5A). In addition, higher percentage of
CD38+ HLA-DR+ cells appeared in memory/effector cells
than naïve subset both in HCV persistent infected indivi-
duals and healthy controls (Figure 5A). Moreover, a signif-
icant correlation between percentage of CD8+ CD38+
H L A - D R +Tc e l l sa n dH C Vv i r a ll o a dw a sf o u n di na l l
CD8+ T cell subsets ((p < 0.05, Figure 5B).
Discussion
It is widely accepted that HCV-specific CD8+ T cells play
an essential role in immune responses to HCV infection
and duration and intensity of CD8+ T cell immunity are
closely correlated with progression of acute HCV infection
[6,36-39]. The maturation and maintenance of CD8+
memory T cells are characterized by their ability to
Figure 1 Distribution of CD8+ T cell subsets in HCV-infected patients and healthy controls according to the expression of CD45RA
and CD27. (A). Representative Dot plots analysis showing the gating strategy to define CD8+ T cell subsets using CD45RA and CD27. The plots
from (a) to (f) were first gated on lymphocytes by FSC and SSC, then the CD3+CD4-CD8+ subpopulation was defined by the expression of
CD45RA and CD27. (B). Comparison of CD8+ T cell subsets in chronic HCV infection (dark grey boxes) and healthy controls (open boxes). Data
were shown as median and interquartile range values. Symbols: ●, outlier values (more than 1.5 times the interquartile range). (C). Dot plots
analysis showing that the majority of CD8+ CD45RA+CD27+ naïve T cells presented CD45RA+CCR7+ phenotype. A representative dot plot result
of five HCV patients and five healthy donors.
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Page 4 of 9Figure 2 Comparison of PD-1, CD38, HLA-DR and CD127 expression on total CD8+ T cells in HCV-infected patients. (A). Representative
histogram showing different patterns of PD-1, CD38, HLA-DR and CD127 expression on whole CD8+ T cells in chronic HCV (dark area) infection,
healthy controls (dark grey area) and isotype antibodies controls (grey area). (B). Statistic analysis of PD-1, CD38, HLA-DR and CD127 expression
on total CD8+ T cells in chronic HCV (△) infection and healthy controls (○). Data were presented as mean fluorescence intensity (MFI) (top
panel) and percentage of positive cells (low panel). Graphs showed vertical scatter plots and median lines.
Figure 3 Comparison of PD-1(A), CD38 (B), HLA-DR(C) and CD127 (D)e x p r e s s i o no nC D 8 +Tc e l ls u bsets (naïve, TCM, TEM and
TEMRA). Data were presented as MFI (top panel) and percentage of positive cells (low panel) between chronic HCV infection (dark grey boxes)
and healthy controls (open boxes). Graphs showed median and interquartile range values of MFI or of percentages of positive cells. Symbols:
●, outlier values (more than1.5 times the interquartile range).
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antigenic re-challenge [40,41]. Memory T cells confer
immediate protection in peripheral tissues and mediate
recall responses to antigen in secondary lymphoid organs
[42]. T cells consist of distinct populations characterized
by homing capacity and effector function. Effector mem-
ory cells (TEM) migrate to inflammatory peripheral sites
and perform immediate effector function[42]. CD8+ TEM
expressing CD45RA is defined as TEMRA, which repre-
sent the most differentiated type of memory cells and car-
ries the largest amount of perforin and Fas ligand[10,42].
Central memory cells (TCM) usually resident in T cell
areas of secondary lymphoid organs and readily proliferate
and differentiate into TEM in response to antigenic stimu-
lation though they per se have little or no effector function
[15,42]. In this study, we used CD45RA/CD27 instead of
CD45RA/CCR7 to divide CD8+ T cell into four different
subsets (naïve/TCM/TEM/TEMRA) since several studies
have demonstrated that CD45RA+CD27- phenotype
(TEMRA) can be found in EBV, HCV, CMV and HIV car-
riers[43-46]. Our data also showed that more than 90%
percent of CD45RA+CD27+ (naïve) CD8+ T cell was con-
sistent with CD45RA+CCR7+ population both in HCV
chronic infection and healthy controls (Figure 1C), which
further confirm the correspondence of availability of
CD27 and CCR7 in the definition of CD8+ T cell subsets.
As shown in Figure 1B, HCV-infected patients displayed
decreased naïve CD8+ T cells and increased TEMRA sub-
population compared to healthy controls. However, no
correlation was found between CD8+ T cell subsets and
peripheral HCV viral load or ALT level (data not shown).
It is possible that HCV viral persistence would induce
more naïve CD8+ T cells to be activated resulting to
higher proportion of TEMRA CD8+ T cells emerged.
Nevertheless, the activated TEM/TEMRA subsets lose the
ability to clear peripheral HCV virus or intraheptic viral
replication as seen by HCV persistence.
The activation status of HCV infection was higher
than that of healthy controls according to the expression
of CD38 and HLA-DR (Figure 2B, 3 and Figure 5). Since
the balance between activating and inhibitory marker
expression was critical for homeostatic maintenance of
CD8+T cell-mediated immune response[21,47-49], we
hypothesized that long-term activation of CD8+ T cells
might result in enhanced inhibitory marker expression
on effector CD8+ T cells. This hypothesis was proved
by enhancement of PD-1 and CD38/HLA-DR expression
on CD8+ T cells (Figure 3). Interestingly, we found
expression of PD-1 on CD8+ TEM (p < 0.0001) and
TEMRA (p = 0.0015) were positively correlated with
plasma HCV viral load in HCV-infected patients (shown
in Figure 4A). Since PD-1/PD-L1 pathway was involved
in down-regulating function of activated CD8+ T cells
in liver and peripheral circulation[25], it is conceivable
Figure 4 Correlation analysis of expression of PD-1, CD38, HLA-DR and CD127 on total CD8+ T cell and its subsets with HCV plasma
viral load (A) or ALT level (B) in HCV-infected patients.
Shen et al. Virology Journal 2010, 7:310
http://www.virologyj.com/content/7/1/310
Page 6 of 9that enhancement of PD-1 expression on CD8+ T cells
was correlated with capacity of virus replication. Future
study of CD8+ T cells resident in liver may probably
confirm this correlation and provide more information
than current data to assess the role of PD-1/PD-L1
pathway on CD8+ T cell activation, function and HCV
viral replication.
Expression level of HLA-DR, but not CD38, on acti-
vated CD8+ T cell, including memory and effector
subsets, were shown to negatively correlate with circu-
lating HCV viral load (p < 0.05). Unlike HLA-DR, CD38
was considered as a critical marker for T cell activation
since it mainly effects in cell adhesion, signal transduc-
tion and calcium signaling, but not in antigen presenta-
tion process [50]. In accordance with this, this study
demonstrated that HLA-DR was a better indicator than
CD38 to predict the HCV replication in vivo. Interest-
ingly, the proportion of CD38+ HLA-DR+CD8+ T cells
Figure 5 Percentage of CD38+ HLA-DR+ CD8+ T cells in HCV chronically infected patients and its correlation with traditional clinical
indicators. (A) Comparison of percentage of CD38+ HLA-DR+ CD8 T cells on total CD8+ T cell and its subsets in HCV-infected patients (dark
grey boxes) and healthy controls (open boxes). Graphs showed median and interquartile range values of percentages of positive cells. Symbols:
●, outlier values (more than 1.5 times the interquartile range). (B) Correlation analysis of percentage of CD38+ HLA-DR+ population on total
CD8+ T cell and its subsets with HCV plasma viral load or ALT level in chronic HCV infected patients.
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both on total CD8+ T cells and its subsets (Figure 5).
This result indicated that combination of CD38 and
HLA-DR was more accurate to signal the correlation
with HCV viral load in chronic HCV infection than
employment of CD38 or HLA-DR individually.
CD127 displayed distinguishing characteristics in
HCV-infected patients and healthy controls in compari-
son with expression of PD-1, HLA-DR and CD38.
Kaech et al. demonstrated that IL-7 receptor (CD127)/
IL-7 pathway is critical for maintenance of memory
CD8+ T cell homeostasis [28]. In fact, adoptively trans-
ferred CD127+CD8+ T cells but not CD127-CD8+
T cells survived in absence of antigen stimulation by
homeostatic proliferation via CD127[51]. Therefore,
CD127+CD8+ T cells were regarded to have phenotypic
and functional features of TCM, while CD127-CD8+
T cells have features of TEM. In this study, CD127
expression on CD8+ T cells decreased when CD8+
T cells differentiated from TCM to TEM, which is con-
sistent with the results reported previously and further
indicate that lower expression level of CD127 on TCM
and TEM will be closely associated with the impairment
of memory CD8+ T cell homeostasis.
Taken together, PD-1, CD38 and HLA-DR expression
was increased on all CD8+ T cell subsets while CD127
expression was decreased on TCM and TEM subsets
compared to healthy controls. MFI of PD-1 on CD8+
TEM and TEMRA was positively correlated with HCV
viral load while HLA-DR molecules on CD8+ T cell
subsets (memory/effector) were negatively correlated
with HCV viral load in HCV-infected patients.
Therefore, PD-1 might be regarded as a simple and easy-
manipulated CD8+ T cell marker to assess viral replica-
tion in chronic HCV infected patients. These findings
will be helpful to understand the interaction between
maturation/activation and function of CD8+ T cell and
viral replication during HCV long-term persistence.
Conclusion
P D - 1l e v e lo np e r i p h e r a lC D 8 +T E M / T E M R Aw a s
highly correlated with HCV viral load in chronic HCV-
infected patients, which made PD-1 a novel indicator to
evaluate the impairment and dysfunction of host CD8+
T cell immunity as well as HCV viral persistence.
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